干扰素联合瑞贝生治疗宫颈高危型HPV持续感染患者的疗效及对其免疫水平的影响  

Efficacy of interferon combined with Rebacin in the treatment of patients with persistent cervical high-risk HPV infection and its influence on their immune level

作　　者：温美珠 WEN Mei-zhu(Dehua County Hospital,Quanzhou 362500,China)

机构地区：[1]德化县医院,362500

出　　处：《中国现代药物应用》2024年第20期90-93,共4页Chinese Journal of Modern Drug Application

摘　　要：目的分析宫颈高危型人乳头瘤病毒(HPV)持续感染患者采用女性抗毒洁阴复合剂(商品名:瑞贝生)以及干扰素联合治疗的临床疗效及对其免疫水平的影响。方法根据采用治疗方法的不同,将240例宫颈高危型HPV持续感染患者评价分配至观察组和对照组中,每组120例。对照组患者在月经之后3 d开始使用重组人干扰素α2b栓治疗,观察组患者在对照组的治疗基础上同时应用瑞贝生进行治疗。对比两组患者随访6个月的HPV转阴情况、无不良反应发生率、治疗前后的肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平。结果在治疗效果方面,观察组清除率为78.33%,对照组总清除率仅为31.67%。特别是在HPV的完全清除率方面,观察组的66.67%显著优于对照组的23.33%,总清除率同样高出许多(78.33%对比31.67%),这些差异都具有统计学意义(P<0.05)。关于安全性,观察组的无不良反应发生率为70.00%,而对照组稍高为76.67%。尽管两组的安全性表现相似,但统计分析显示这一差异并不显著(P>0.05)。在生物标志物的变化上,两组患者在治疗后的TNF-α水平均显著低于治疗前,而IL-6水平则显著高于治疗前。值得注意的是,观察组的TNF-α平均水平(89.32±23.21)ng/L低于对照组(106.32±22.76)ng/L,IL-6平均水平(9.01±3.43)ng/L则高于对照组(6.54±3.32)ng/L,显示出治疗后生物标志物的差异性也具有统计学意义(P<0.05)结论干扰素联合瑞贝生在宫颈高危型HPV持续感染患者的治疗中能够起到良好的效果,用药安全性高,具有较高的推广价值。Objective To analyze the clinical efficacy of interferon combined with Rebacin in the treatment of patients with persistent cervical high-risk human papillomavirus(HPV)infection and its influence on their immune level.Methods 240 patients with persistent cervical high-risk HPV infection were divided into an observation group and a control group according to the differences in treatment modalities,with 120 patients in each group.Patients in the control group were treated with recombinant human interferonα-2b suppository 3 d after menstruation,and patients in the observation group were treated with Rebacin on the basis of the control group.Both groups were compared in terms of HPV negative-conversion status after 6 months of follow-up,the incidence of no adverse reactions,and the levels of tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)before and after treatment.Results In terms of treatment efficacy,the observation group had a clearance rate of 78.33%,while the control group had a total clearance rate of only 31.67%.Especially in terms of the complete clearance rate of HPV,the observation group's 66.67%was significantly better than the control group's 23.33%,and the total clearance rate was also much higher(78.33%compared to 31.67%),and these differences were statistically significant(P<0.05).Regarding safety,the observation group had a no adverse reaction incidence rate of 70.00%,while the control group had a slightly higher rate of 76.67%.Although the safety performance of the two groups was similar,statistical analysis showed that the difference was not significant(P>0.05).In terms of changes in biomarkers,both groups of patients had significantly lower levels of TNF-αafter treatment compared to before treatment,while IL-6 levels were significantly higher than before treatment.It is worth noting that the average level of TNF-αin the observation group(89.32±23.21)ng/L was lower than that in the control group(106.32±22.76)ng/L,while the average level of IL-6(9.01±3.43)ng/L was higher than that in th

关 键 词：干扰素 女性抗毒洁阴复合剂 人乳头瘤病毒 免疫水平 

分 类 号：R737.33[医药卫生—肿瘤]